Trial Profile
A Study to Evaluate the Efficacy and Safety of Boceprevir or Telaprevir With Pegylated Interferon-Alfa and Ribavirin in HIV/HCV Genotype 1-Coinfected Patients With Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2016
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 23 May 2016 New trial record